FUNCTIONAL EXPRESSION OF HUMAN-CD28 IN MURINE T-CELL HYBRIDOMAS

被引:18
作者
COUEZ, D [1 ]
PAGES, F [1 ]
RAGUENEAU, M [1 ]
NUNES, J [1 ]
KLASEN, S [1 ]
MAWAS, C [1 ]
TRUNEH, A [1 ]
OLIVE, D [1 ]
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406
关键词
D O I
10.1016/0161-5890(94)90137-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD28 is a 44 kDa Ig superfamily cell surface molecule expressed on most mature T cells. Through its interaction with the recently identified B7/BB1 counter-receptor, it is believed to play an important role as a co-stimulator of T cells along with the TCR-CD3 complex. Activation of T cells with CD28 mAbs synergizes with TCR-CD3 and CD2 stimulation, resulting in long term T cell proliferation, differentiation of cytotoxic T cells and production of large amounts of cytokines. In order to further delineate the role of CD28 in signal transduction and T cell activation, human CD28 was transfected into CD3+ murine T cell hybridomas. High levels of cell surface CD28 expression was achieved by protoplast fusion. The transfected molecule retained all the native CD28 mAb epitopes found on human T cells. In these transfectants, CD28 mAbs, similarly to CD3 mAbs, were able to induce Ca2+ mobilization, IL-2 promoter induction (measured as beta-galactosidase activity in T cells hybridomas pre-transfected with the IL-2-lac Z reporter gene), IL-2 secretion, TNF alpha production and apoptosis (observed as growth arrest and genome fragmentation). The parental host cells, or cells transfected with vector alone, responded only to mAbs to CD3. IL-2 secretion in the transfectants was obtained using either an IgM mAb to CD28 or IgG mAbs presented on the surface of IgG-FcR+ B lymphoma cells. Optimal activation via CD28 was inhibited by suboptimal concentrations of soluble CD3 mAb, suggesting an interaction between the two pathways. The immunosuppressive drugs Cyclosporin A and FK506 completely blocked CD28 and CD3 mediated IL-2 production in these transfectants whereas rapamycin had only a partial inhibitory effect. Finally, since the transfected human CD28 molecule confers full functional responsiveness to the, murine T cell hybridomas without the need for costimulators such as PMA, this model is ideal for studying the structure-function relationships of the CD28 molecule as well as the transmembrane and cytoplasmic associations implied in CD28 signaling.
引用
收藏
页码:47 / 57
页数:11
相关论文
共 52 条
  • [21] HUMAN T-CELL ACTIVATION .2. A NEW ACTIVATION PATHWAY USED BY A MAJOR T-CELL POPULATION VIA A DISULFIDE-BONDED DIMER OF A 44-KILODALTON POLYPEPTIDE (9.3 ANTIGEN)
    HARA, T
    FU, SM
    HANSEN, JA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (06) : 1513 - 1524
  • [22] CD28-MEDIATED SIGNALING CO-STIMULATES MURINE T-CELLS AND PREVENTS INDUCTION OF ANERGY IN T-CELL CLONES
    HARDING, FA
    MCARTHUR, JG
    GROSS, JA
    RAULET, DH
    ALLISON, JP
    [J]. NATURE, 1992, 356 (6370) : 607 - 609
  • [23] HARPER K, 1991, J IMMUNOL, V147, P1037
  • [24] JUNE CH, 1989, J IMMUNOL, V143, P153
  • [25] T-CELL PROLIFERATION INVOLVING THE CD28 PATHWAY IS ASSOCIATED WITH CYCLOSPORINE-RESISTANT INTERLEUKIN-2 GENE-EXPRESSION
    JUNE, CH
    LEDBETTER, JA
    GILLESPIE, MM
    LINDSTEN, T
    THOMPSON, CB
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1987, 7 (12) : 4472 - 4481
  • [26] ANTIGEN PRESENTATION BY IA+ B-CELL HYBRIDOMAS TO H-2-RESTRICTED T-CELL HYBRIDOMAS
    KAPPLER, J
    WHITE, J
    WEGMANN, D
    MUSTAIN, E
    MARRACK, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (11): : 3604 - 3607
  • [27] ANTIGEN-INDUCIBLE, H-2-RESTRICTED, INTERLEUKIN-2-PRODUCING T-CELL HYBRIDOMAS - LACK OF INDEPENDENT ANTIGEN AND H-2 RECOGNITION
    KAPPLER, JW
    SKIDMORE, B
    WHITE, J
    MARRACK, P
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1981, 153 (05) : 1198 - 1214
  • [28] THE CD28 LIGAND B7/BB1 PROVIDES COSTIMULATORY SIGNAL FOR ALLOACTIVATION OF CD4+ T-CELLS
    KOULOVA, L
    CLARK, EA
    SHU, G
    DUPONT, B
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 173 (03) : 759 - 762
  • [29] LAFAGEPOCHITALOFF M, 1990, IMMUNOGENETICS, V31, P198
  • [30] LEDBETTER JA, 1985, J IMMUNOL, V135, P2331